A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)

Protocol No
RHEU-PROMETHEUS-ATHENA
Staff Member
Mary Ellen Csuka
Phase
II
Summary

This project is being done to find out whether an investigational drug for systemic sclerosis associated with interstitial lung disease (SScILD), PRA023, is better than placebo.
Objective
PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (ATHENA-SSc-ILD)
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ILD/IPF, Lungs and Breathing
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05270668